PDCD1 and breast cancer: Overall, our findings suggest that anti-PD-1 treatment holds considerable potential in boosting CTLs’ cytotoxicity through HLA-DR, beyond mere stimulation, especially against BC subtypes with elevated PD-L1 expression (Figure 4A, Supplementary Figure S8, Supplementary Table S1).